Correction: The impact of a one-dose versus two-dose oral cholera vaccine regimen in outbreak settings: A modeling study (PLoS Med, (2015), 12(8), 10.1371/journal.pmed.1001867;The Impact of a One-Dose versus Two-Dose Oral Cholera Vaccine Regimen in Outbreak Settings: A Modeling Study

PLoS Medicine

Volumn 12, Issue 8, 2015, Pages

  Azman, Andrew S ^a   Luquero, Francisco J ^b   Ciglenecki, Iza ^c   Grais, Rebecca F ^b   Sack, David A ^a   Lessler, Justin ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b EPICENTRE   (France)

^c MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA VACCINE;

ARTICLE; BIOLOGICAL ACCIDENT; CHOLERA; DEATH; DISEASE PREDISPOSITION; DISEASE SEVERITY; DISEASE TRANSMISSION; EPIDEMIC; HUMAN; IMMUNITY; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; VACCINATION; GUINEA; HAITI; MASS IMMUNIZATION; ORAL DRUG ADMINISTRATION; TRANSMISSION; ZIMBABWE;

ADMINISTRATION, ORAL; CHOLERA; CHOLERA VACCINES; DISEASE OUTBREAKS; GUINEA; HAITI; HUMANS; MASS VACCINATION; ZIMBABWE;

EID: 84940754922     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001989     Document Type: Erratum

References (42)

1. Ali M, Lopez AL, You YA, Kim YE, Sah B, Maskery et al. The global burden of cholera. Bull World Health Org. 2012;90:209–218A. doi: 10.2471/BLT.11.093427 22461716
2. Mengel MA, Delrieu I, Heyerdahl L, Gessner BD, Nair GB, Takeda Y, Cholera outbreaks in Africa. In: Cholera outbreaks. Heidelberg: Springer; 2014. pp. 117–144.
3. Bhattacharya S, Black R, Bourgeois L, Clemens J, Deen JL, Dougan G, et al. The cholera crisis in Africa. Science. 2009;324:885. doi: 10.1126/science.1173890 19443768
4. Barzilay EJ, Schaad N, Magloire R, Mung KS, Boncy J, Dahourou et al. Cholera surveillance during the Haiti epidemic—the first 2 years. N Engl J Med. 2013;368:599–609. doi: 10.1056/NEJMoa1204927 23301694
5. Luquero FJ, Grout L, Ciglenecki I, Sakoba K, Traore B, Heile et al. Use of Vibrio cholerae vaccine in an outbreak in Guinea. N Engl J Med. 2014;370:2111–2120. doi: 10.1056/NEJMoa1312680 24869721
6. World Health Organization. Cholera vaccines: WHO position paper—recommendations. Vaccine. 2010;28:4687–4688. doi: 10.1016/j.vaccine.2010.05.008 20483196
7. World Health Organization. Cholera, 2013. Wkly Epidemiol Rec. 2014;89:345–356.
8. Mohammed AJ, Al Awaidy S, Bawikar S, Kurup PJ, Elamir E, Shaban MMA, et al. Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med. 2010;362:2351–2359. doi: 10.1056/NEJMoa0909383 20573923
9. Guerin PJ, Naess LM, Fogg C, Rosenqvist E, Pinoges L, Bajunirwe F, et al. Immunogenicity of fractional doses of tetravalent A/C/Y/W135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in Uganda. PLoS Negl Trop Dis. 2008;2:e342. doi: 10.1371/journal.pntd.0000342 19048025
10. Viechtbauer W, Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36:1–48.
11. Newcombe RG, MOVER-R confidence intervals for ratios and products of two independently estimated quantities. Stat Methods Med Res. 2013 Oct 9. doi: 10.1177/0962280213502144
12. Anderson RM, May RM, Infectious diseases of humans: dynamics and control. Oxford: Oxford University Press; 1991.
13. Black RE, Levine MM, Clements ML, Young CR, Svennerholm A, Holmgren J, Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin. Infect Immun. 1987;55:1116–1120. 3552989
14. Halloran ME, Longini IM, JrStruchiner CJ, Design and analysis of vaccine studies. New York: Springer; 2009.
15. Morris JG, Cholera—modern pandemic disease of ancient lineage. Emerg Infect Dis. 2011;17:2099–2104. doi: 10.3201/eid1711.111109 22099113
16. Azman AS, Rudolph KE, Cummings DAT, Lessler J, The incubation period of cholera: a systematic review. J Infect. 2013;66:432–438. doi: 10.1016/j.jinf.2012.11.013 23201968
17. Weil AA, Khan AI, Chowdhury F, LaRocque RC, Faruque ASG, Ryan ET, et al. Clinical outcomes in household contacts of patients with cholera in Bangladesh. Clin Infect Dis. 2009;49:1473–1479. doi: 10.1086/644779 19842974
18. Ciglenecki I, Sakoba K, Luquero FJ, Heile M, Itama C, Mengel M, et al. Feasibility of mass vaccination campaign with oral cholera vaccines in response to an outbreak in Guinea. PLoS Med. 2013;10:e1001512. doi: 10.1371/journal.pmed.1001512 24058301
19. Luquero FJ, Banga CN, Remartínez D, Palma PP, Baron E, Grais RF, Cholera epidemic in Guinea-Bissau (2008): the importance of “place.” PLoS ONE. 2011;6:e19005. doi: 10.1371/journal.pone.0019005 21572530
20. Reyburn R, Clemens JD, Deen JL, Grais RF, Bhattacharya SK, Sur D, et al. The case for reactive mass oral cholera vaccinations. PLoS Negl Trop Dis. 2011;5:e952. doi: 10.1371/journal.pntd.0000952 21283614
21. Ministere de la Sante Publique et de la Population. Rapport de cas—30 Septembre 2011. Available: http://mspp.gouv.ht/site/downloads/Rapport%20journalier%20MSPP%20du%2030%20septembre%202011.pdf. Accessed 15 June 2014.
22. Ionides EL, Nguyen D, Atchadé Y, Stoev S, King AA, Inference for dynamic and latent variable models via iterated, perturbed Bayes maps. Proc Natl Acad Sci U S A. 2015;112:719–724. doi: 10.1073/pnas.1410597112 25568084
23. R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2011. Available: http://www.R-project.org/. Accessed 23 July 2015.
24. Khatib AM, Ali M, Seidlein von L, Kim DR, Hashim R, Reyburn R, et al. Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study. Lancet Infect Dis. 2012;12:837–844. doi: 10.1016/S1473-3099(12)70196-2 22954655
25. Sur D, Lopez AL, Kanungo S, Paisley A, Manna B, Ali M, et al. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:1694–1702. doi: 10.1016/S0140-6736(09)61297-6 19819004
26. Sanchez JL, Vasquez B, Begue RE, Meza R, Castellares G, Cabezas C, et al. Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet. 1994;344:1273–1276. 7967990
27. Clemens JD, Harris JR, Khan MR, Kay BA, Yunus M, Svennerholm A, et al. Field trial of oral cholera vaccines in Bangladesh. Lancet. 1986;328:124–127.
28. Lucas MES, Deen JL, von Seidlein L, Wang XY, Ampuero J, Puri M, et al. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N Engl J Med. 2005;352:757–67. 15728808
29. Date KA, Vicari A, Hyde TB, Mintz E, Danovaro-Holliday MC, Henry A, et al. Considerations for oral cholera vaccine use during outbreak after earthquake in Haiti, 2010–2011. Emerg Infect Dis. 2011;17:2105–2112. doi: 10.3201/eid1711.110822 22099114
30. Chao DL, Halloran ME, Longini IM, Vaccination strategies for epidemic cholera in Haiti with implications for the developing world. Proc Natl Acad Sci U S A. 2011;108:7081–7085. doi: 10.1073/pnas.1102149108 21482756
31. Andrews JR, Basu S, Transmission dynamics and control of cholera in Haiti: an epidemic model. Lancet. 2011;377:1248–1255. doi: 10.1016/S0140-6736(11)60273-0 21414658
32. Azman AS, Luquero FJ, Rodrigues A, Palma PP, Grais RF, Banga CA, et al. Urban cholera transmission hotspots and their implications for reactive vaccination: evidence from Bissau city, Guinea Bissau. PLoS Negl Trop Dis. 2012;6:e1901. doi: 10.1371/journal.pntd.0001901 23145204
33. Constantin de Magny G, Guégan J-F, Petit M, Cazelles B, Regional-scale climate-variability synchrony of cholera epidemics in West Africa. BMC Infect Dis. 2007;7:20. 17371602
34. Kanungo S, Paisley A, Lopez AL, Bhattacharya M, Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial. Vaccine 2009;27:6887–6893. doi: 10.1016/j.vaccine.2009.09.008 19761838
35. Clemens JD, Sack DA, Harris JR, Van Loon F, Chakraborty J, Ahmed F, et al. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet. 1990;335:270–273. 1967730
36. Albert MJ, Qadri F, Wahed MA, Ahmed T, Rahman ASMH, Ahmed F, et al. Supplementation with zinc, but not vitamin A, improves seroconversion to vibriocidal antibody in children given an oral cholera vaccine. J Infect Dis. 2003;187:909–913. 12660937
37. Sack DA, Clemens JD, Huda S, Harris JR, Khan MR, Chakraborty J, et al. Antibody responses after immunization with killed oral cholera vaccines during the 1985 vaccine field trial in Bangladesh. J Infect Dis. 1991;164:407–411. 1856488
38. Clemens JD, Stanton BF, Chakraborty J, Sack DA, Khan MR, Huda S, et al. B subunit-whole cell and whole cell-only oral vaccines against cholera: studies on reactogenicity and immunogenicity. J Infect Dis. 1987;155:79–85. 3540139
39. Hashim R, Khatib AM, Enwere G, Park JK, Reyburn R, Ali M, et al. Safety of the recombinant cholera toxin B subunit, killed whole-cell (rBS-WC) oral cholera vaccine in pregnancy. PLoS Negl Trop Dis. 2012;6:e1743. doi: 10.1371/journal.pntd.0001743 22848772
40. Moodley K, Hardie K, Selgelid MJ, Waldman RJ, Strebel P, Rees H, et al. Ethical considerations for vaccination programmes in acute humanitarian emergencies. Bull World Health Organ. 2013;91:290–297. doi: 10.2471/BLT.12.113480 23599553
41. Mukandavire Z, Liao S, Wang J, Gaff H, Smith DL, Morris JG, Estimating the reproductive numbers for the 2008–2009 cholera outbreaks in Zimbabwe. Proc Natl Acad Sci U S A. 2011;108:8767–8772. doi: 10.1073/pnas.1019712108 21518855
42. Mukandavire Z, Smith DL, Morris JG, JrCholera in Haiti: reproductive numbers and vaccination coverage estimates. Sci Rep. 2013;3:997. doi: 10.1038/srep00997 23308338